Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Junshi Bio Says PD-1 Meets Endpoints in Esophageal Cancer

Shanghai Junshi Biosciences stopped the Phase III trial of its anti-PD-1 candidate early because toripalimab met its survival endpoints at an interim review. Toripalimab was administered together with paclitaxel/cisplatin as a first-line treatment for patients with advanced esophageal squamous cell carcinoma. The combination met the pre-specified primary endpoints of Progression Free Survival and Overall Survival in a double-blind Phase III trial. Toripalimab is already approved for three other indications in China. More details... Stock Symbols: (HK: 1877; SHA: 688180) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.